科達製造(600499.SH):擬推2025年員工持股計劃
格隆匯3月26日丨科達製造(600499.SH)公佈2025年員工持股計劃,本員工持股計劃股票來源為公司回購專用證券賬户回購的科達製造A股普通股股票。本次員工持股計劃經公司股東大會審議通過後,擬通過非交易過户等法律法規允許的方式受讓公司回購的股票59,999,862股,佔公司現有股本總額約為3.13%,股票購買價格為4.14元/股。本員工持股計劃的資金來源為員工合法薪酬、自籌資金以及法律法規允許的其他方式,公司不以任何方式向持有人提供墊資、擔保、借貸等財務資助。本員工持股計劃擬籌集資金總額上限為24,840萬元,以“份”作為認購單位,每份份額為1.00元,具體份額根據實際出資繳款金額確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.